AI has changed what’s easy in protein engineering. Structure prediction, de novo binder and antibody design, developability and immunogenicity triage, sequence optimization - work that took years now takes months and even days. The harder question is what that actually buys us. A pipeline moves at the speed of its slowest step, and a step getting cheaper only shortens the timeline if that step was the one holding things up.
Our discussion takes that question seriously across the modalities defining the field today - antibodies, ADCs, nanobodies - and look into the future of engineered…

Hosted by Kia Winslow, Anastasia Shindyapina, PhD & MBC BioLabs